[{"id":"6930bd13-a689-4284-b6bf-affbebb0e167","acronym":"","url":"https://clinicaltrials.gov/study/NCT05366816","created_at":"2022-05-09T11:56:34.398Z","updated_at":"2024-07-02T16:35:32.170Z","phase":"Phase 2","brief_title":"ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST","source_id_and_acronym":"NCT05366816","lead_sponsor":"University of Miami","biomarkers":" KIT","pipe":" | ","alterations":" KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 10/17/2023","start_date":" 10/17/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2023-10-23"},{"id":"adc60e89-0c9c-4cc8-bd12-3a3c5b7efc48","acronym":"","url":"https://clinicaltrials.gov/study/NCT01543113","created_at":"2021-01-18T06:31:19.399Z","updated_at":"2024-07-02T16:35:47.212Z","phase":"","brief_title":"cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project","source_id_and_acronym":"NCT01543113","lead_sponsor":"Rennes University Hospital","biomarkers":" KIT • RAS","pipe":" | ","alterations":" NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation"],"overall_status":"Completed","enrollment":" Enrollment 288","initiation":"Initiation: 01/01/2011","start_date":" 01/01/2011","primary_txt":" Primary completion: 03/01/2012","primary_completion_date":" 03/01/2012","study_txt":" Completion: 02/01/2014","study_completion_date":" 02/01/2014","last_update_posted":"2023-05-24"},{"id":"146c9420-e555-47fd-8fcd-cac5b5961016","acronym":"REGISTRI","url":"https://clinicaltrials.gov/study/NCT02638766","created_at":"2021-01-18T12:50:04.935Z","updated_at":"2025-02-25T17:22:57.842Z","phase":"Phase 2","brief_title":"Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST","source_id_and_acronym":"NCT02638766 - REGISTRI","lead_sponsor":"Grupo Espanol de Investigacion en Sarcomas","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation • KIT exon 13 mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Stivarga (regorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 15","initiation":"Initiation: 11/01/2015","start_date":" 11/01/2015","primary_txt":" Primary completion: 08/31/2021","primary_completion_date":" 08/31/2021","study_txt":" Completion: 08/31/2021","study_completion_date":" 08/31/2021","last_update_posted":"2023-03-27"},{"id":"ea5d6031-d473-42c0-8a28-91a62279cacc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03609424","created_at":"2021-01-18T17:44:34.659Z","updated_at":"2025-02-25T15:43:08.795Z","phase":"Phase 1/2","brief_title":"PDR001 Plus Imatinib for Metastatic or Unresectable GIST","source_id_and_acronym":"NCT03609424","lead_sponsor":"Asan Medical Center","biomarkers":" KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1","pipe":" | ","alterations":" KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation","tags":["KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 9 mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 02/14/2019","start_date":" 02/14/2019","primary_txt":" Primary completion: 11/11/2021","primary_completion_date":" 11/11/2021","study_txt":" Completion: 11/11/2021","study_completion_date":" 11/11/2021","last_update_posted":"2023-01-02"},{"id":"65aa546b-6373-4d3e-bd0b-ba34a643210e","acronym":"ZJGIST-01","url":"https://clinicaltrials.gov/study/NCT04933669","created_at":"2021-06-22T15:52:32.553Z","updated_at":"2024-07-02T16:36:23.163Z","phase":"Phase 2","brief_title":"Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT04933669 - ZJGIST-01","lead_sponsor":"First Affiliated Hospital of Zhejiang University","biomarkers":" KIT • PDGFRA • ANO1","pipe":" | ","alterations":" KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation","tags":["KIT • PDGFRA • ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib"],"overall_status":"Recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 09/07/2021","start_date":" 09/07/2021","primary_txt":" Primary completion: 12/31/2029","primary_completion_date":" 12/31/2029","study_txt":" Completion: 12/31/2029","study_completion_date":" 12/31/2029","last_update_posted":"2021-10-12"},{"id":"c58ef208-7673-4496-a586-1341950ca581","acronym":"POETIG","url":"https://clinicaltrials.gov/study/NCT03171389","created_at":"2021-01-18T15:38:08.310Z","updated_at":"2024-07-02T16:37:21.526Z","phase":"Phase 2","brief_title":"POETIG Trial - POnatinib After rEsisTance to Imatinib in GIST","source_id_and_acronym":"NCT03171389 - POETIG","lead_sponsor":"Sebastian Bauer","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" KIT mutation • PDGFRA mutation • KIT exon 13 mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • PDGFRA mutation • KIT exon 13 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Iclusig (ponatinib)"],"overall_status":"Unknown status","enrollment":" Enrollment 81","initiation":"Initiation: 03/22/2017","start_date":" 03/22/2017","primary_txt":" Primary completion: 09/22/2018","primary_completion_date":" 09/22/2018","study_txt":" Completion: 09/22/2020","study_completion_date":" 09/22/2020","last_update_posted":"2017-05-31"}]